6 documents found, page 1 of 1
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloid...
Brannagan, Thomas H.; Coelho, Teresa; Wang, Annabel K.; Polydefkis, Michael J.; Dyck, Peter J.; Berk, John L.; Drachman, Brian; Gorevic, PeterBackground: Hereditary transthyretin amyloidosis (hATTR/ATTRv) results from the deposition of misfolded transthyretin (TTR) throughout the body, including peripheral nerves. Inotersen, an antisense oligonucleotide inhibitor of hepatic TTR production, demonstrated a favorable efficacy and safety profile in patients with the polyneuropathy associated with hATTR in the NEURO-TTR (NCT01737398) study. We report long...
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with ...
Adams, David; Ando, Yukio; Beirão, João; Coelho, Teresa; Gertz, Morie A.; Gillmore, Julian D.; Hawkins, Philip N.; Lousada, Isabelle; Suhr, Ole B.Amyloid transthyretin (ATTR) amyloidosis with polyneuropathy (PN) is a progressive, debilitating, systemic disease wherein transthyretin protein misfolds to form amyloid, which is deposited in the endoneurium. ATTR amyloidosis with PN is the most serious hereditary polyneuropathy of adult onset. It arises from a hereditary mutation in the TTR gene and may involve the heart as well as other organs. It is critica...
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediate...
Adams, David; Polydefkis, Michael; González-Duarte, Alejandra; Wixner, Jonas; Kristen, Arnt V.; Schmidt, Hartmut H.; Berk, John L.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label ex...
Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyr...
Merlini, Giampaolo; Coelho, Teresa; Waddington Cruz, Márcia; Li, Huihua; Stewart, Michelle; Ebede, BenIntroduction: The effects of tafamidis on mortality in Val30Met and non-Val30Met patients with transthyretin amyloidosis with polyneuropathy (ATTR-PN) were evaluated. Methods: The analyses were based on cumulative data from the Val30Met patients in the 18-month double-blind registration study and its 12-month open-label extension study, the non-Val30Met patients of the 12-month open-label study, and both patien...
Inotersen preserves or improves quality of life in hereditary transthyretin amy...
Coelho, Teresa; Yarlas, Aaron; Waddington-Cruz, Marcia; White, Michelle K.; Sikora Kessler, Asia; Lovley, Andrew; Pollock, Michael; Guthrie, SpencerObjective: To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo. Methods: Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-blind, placebo-controlled study of inotersen in patients with hATTR amyloidosis with polyneuropathy. At baseline and...
Transthyretin deposition in the eye in the era of effective therapy for heredit...
Buxbaum, Joel N.; Brannagan, Thomas; Buades-Reinés, Juan; Cisneros, Eugenia; Conceição, isabel; Kyriakides, Theodoros; Merlini, Giampaolo; Obici, LauraBackground: Ocular abnormalities have been known to occur in hereditary amyloidotic polyneuropathy since the 1950s. While vitreous opacities and scalloped pupils were described early it has become evident that every component of the eye from the conjunctiva to the retinal vasculature can be involved. Reports from the major centres in Japan, Portugal and Sweden, which primarily treat patients with ATTRV30M, have...